Anipamil 

Anipamil is a long-acting calcium channel blocker, used for the treatment of cardiovascular disease.

Anipamil (40 mg, p.o.)-treated 2K-1C rabbits reveal absent or negligible intimal thickening and a decrease of postnatal-type SMC from the underlying media. Anipamil inhibits the growth of SMC accompanied by the expression of SM-MyHC in all SMC, ie, the appearance of a more differentiated cell phenotype compared to control cultures^[1]. In the arrhythmic assay, anipamil (1.0 mg/kg + 0.10 mg/kg/min infusion, n=8 or 5.0 mg/kg + 0.50 mg/kg/min infusion, n=12) reduces VT but not VF^[2]. In rats with subtotal (five-sixths) nephrectomy treated with anipamil (0.5 mg/kg/day, p.o.), the mortality is less, and the mean arterial blood pressure is also more well controlled, and the serum creatinine concentration is lower than control group. The anipamil (2 mg/kg/day)-treated group exhibits significantly greater protection of renal function than does the hydralazine-treated group for the same level of blood pressure control^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

520.79

C₃₄H₅₂N₂O₂

83200-10-6

Liquid (Density: 0.983±0.06 g/cm³)

Colorless to light yellow

N#CC(CCCN(CCC1=CC=CC(OC)=C1)C)(CCCCCCCCCCCC)C2=CC=CC(OC)=C2

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Pauletto P, et al. Anipamil prevents intimal thickening in the aorta of hypertensive rabbits through changes in smooth muscle cell phenotype. Am J Hypertens. 1996 Jul;9(7):687-94.  [Content Brief]

  [2]. Pugsley MK, et al. Effects of anipamil, a long acting analog of verapamil, in pigs subjected to myocardial ischemia. Life Sci. 1995;57(12):1219-31.  [Content Brief]

  [3]. Jarusiripipat C, et al. Effect of long-acting calcium entry blocker (anipamil) on blood pressure, renal function and survival of uremic rats. J Pharmacol Exp Ther. 1992 Jan;260(1):243-7.  [Content Brief]